| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TIMD4 |
| Uniprot No | Q96H15 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-315aa |
| 氨基酸序列 | ETVVTEVLGHRVTLPCLYSSWSHNSNSMCWGKDQCPYSGCKEALIRTDGM RVTSRKSAKYRLQGTIPRGDVSLTILNPSESDSGVYCCRIEVPGWFNDVK INVRLNLQRASTTTHRTATTTTRRTTTTSPTTTRQMTTTPAALPTTVVTT PDLTTGTPLQMTTIAVFTTANTCLSLTPSTLPEEATGLLTPEPSKEGPIL TAESETVLPSDSWSSVESTSADTVLLTSKESKVWDLPSTSHVSMWKTSDS VSSPQPGASDTAVPEQNKTTKTGQMDGIPMSMKNEMPISQL |
| 预测分子量 | 35 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TIMD4重组蛋白的模拟参考文献示例(注：内容为模拟生成，实际文献需通过学术数据库验证)：
---
1. **文献名称**: *TIMD4 Promotes Macrophage-mediated Clearance of Apoptotic Cells via Binding to Phosphatidylserine*
**作者**: Smith A, et al.
**摘要**: 研究报道了重组TIMD4蛋白通过结合凋亡细胞表面的磷脂酰丝氨酸，增强巨噬细胞的吞噬功能，揭示了其在炎症调控中的潜在作用机制。
2. **文献名称**: *Structural Insights into TIMD4 Interaction with CD155 and Its Role in T-cell Regulation*
**作者**: Chen L, et al.
**摘要**: 通过X射线晶体学解析重组TIMD4蛋白与配体CD155的结合结构，阐明了其免疫检查点功能，为肿瘤免疫治疗提供了新靶点。
3. **文献名称**: *Recombinant TIMD4 Attenuates Atherosclerosis by Modulating Cholesterol Efflux in Macrophages*
**作者**: Wang Y, et al.
**摘要**: 实验表明，重组TIMD4蛋白通过促进巨噬细胞胆固醇外流，减少动脉粥样硬化斑块形成，提示其作为心血管疾病治疗策略的可能性。
4. **文献名称**: *TIMD4 as a Negative Regulator of Autoimmunity: Evidence from Recombinant Protein-based Animal Models*
**作者**: Kimura T, et al.
**摘要**: 在小鼠模型中，注射重组TIMD4蛋白可抑制自身反应性T细胞活化，显著缓解类风湿性关节炎症状，证明其免疫抑制功能。
---
建议通过PubMed或Web of Science检索关键词“TIMD4 recombinant protein”获取真实文献，并核对作者及摘要准确性。
**Background of TIMD4 Recombinant Protein**
TIMD4 (T-cell immunoglobulin and mucin domain-containing protein 4) is a transmembrane protein belonging to the TIM family, which plays critical roles in immune regulation. Initially identified for its involvement in T-cell signaling and immune tolerance, TIMD4 is structurally characterized by an immunoglobulin variable (IgV) domain, a mucin-like domain, a transmembrane region, and a cytoplasmic tail. It shares homology with other TIM family members, such as TIM1 and TIM3. which are known to modulate T-cell activation, apoptosis, and cytokine production.
Functionally, TIMD4 is implicated in mediating phosphatidylserine (PS)-dependent recognition and engulfment of apoptotic cells, a process essential for maintaining tissue homeostasis and preventing autoimmunity. It acts as a PS receptor on antigen-presenting cells (e.g., macrophages and dendritic cells), facilitating the clearance of dying cells and modulating immune responses. Dysregulation of TIMD4 has been linked to autoimmune disorders, chronic inflammation, and cancer, highlighting its therapeutic potential.
Recombinant TIMD4 protein is engineered using expression systems (e.g., mammalian or insect cells) to produce a purified, bioactive form for research. It enables the study of TIMD4-ligand interactions, signaling pathways, and its role in immune regulation. Researchers utilize this tool to explore mechanisms underlying autoimmune diseases, tumor immune evasion, and infection responses. Additionally, recombinant TIMD4 serves as a candidate for developing diagnostic or therapeutic agents targeting immune-related pathologies. Current studies focus on elucidating its dual roles in pro-inflammatory and anti-inflammatory contexts, aiming to harness its regulatory functions for clinical applications.
×
